Government policies for treating drug addicts in England are flawed and “doomed to failure”, a think tank says.
The Centre for Policy Studies says rehabilitation is a better use of the £3.6bn now spent on treating users with drug substitutes like methadone and keeping them on benefits each year.

But it says plans to reward groups which treat addicts so they can return to work are open to manipulation.

The Department of Health said it aimed to get users “off drugs for good”.

The coalition government wants to change the way drug addiction is tackled, with more people with problems diverted away from prison and into treatment as part of what it calls a “rehabilitation revolution”.

Part of this involves rewarding treatment providers who show addicts have improved their health and employment prospects.

A report from the right-of-centre think tank, which has links to the Conservative Party, says these payment by results schemes were being run by the very organisations “responsible for the current failure of policy”.

It says the current annual cost of maintaining treatment for 320,000 problem drug users is made up of £1.7bn in benefits, £1.2bn for looking after their children and £730m for prescribing the heroin substitute methadone.

Kathy Gyngell, Centre of Policy Studies: “The Department of Health has been paying 153,000 people to be on methadone”

The think tank calls for “a real transfer of power from large distant organisations to small innovative providers” for rehabilitation.

It says such units have a better chance of getting addicts off drugs completely, adding: “There is one simple measure of success: That of six months abstinence from drugs.”

According to the report’s author Kathy Gyngell, chairwoman of the prisons and addictions policy forum at the CPS, prescribing methadone to addicts delays their recovery.

She told the BBC: “The state is subsidising people to be any number of years on methadone, which has turned out not to be a cheap option and will only subsidise the tiniest proportion – 2% – to go into a rehabilitation unit that would actually free them from dependency and allow them to live their life.”

A Department of Health spokesman said: “The 2010 Drug Strategy is fundamentally different from those that have gone before.

“Instead of focusing primarily on reducing the harms caused by drug misuse, our approach will be to go much further and offer every support for people to choose recovery as an achievable way out of dependence.”

He added: “Work is under way to support local recovery systems tailored to the needs of communities, many of which are already showing positive results.”

From: http://www.bbc.co.uk/news/uk-13826759

Health Direct has for a long time noted the costly failure that is the current policy on drugs. On August 02, 2006 in Risks of taking drugs compared- Scientific review of dangers of drugtaking- Drugs, the real deal

we reproduced the first ranking based upon scientific evidence of harm to both individuals and society.

It was devised by government advisers – then ignored by ministers because of its controversial findings.

The analysis was carried out by David Nutt, the then senior member of the Advisory Council on the Misuse of Drugs, and Colin Blakemore, the chief executive of the Medical Research Council.
http://www.healthdirect.co.uk/2006/08/risks-of-taking-drugs-compared.html

Legal highs are becoming a bigger problem than illegal drugs with many young people wrongly believing they are safe.
Alan Andrews, an ex-heroin addict who runs a Llanelli-based drug intervention centre, said some legal drugs were stronger than illegal counterparts.

The programme has investigated the issue of legal highs, more than a year after the drug mephedrone, or meow meow, was banned.

Legal highs are substances that are manufactured in a laboratory which do not fall under the current legislation of banned substances under the Misuse of Drugs Act, according to Dr Mohan Da Silva, lead clinician for charity Kaleidoscope Wales.

Undercover recording has found shops breaking the law by selling some of these drugs for human consumption.

Mr Andrews, managing director of Chooselife, said: “It’s becoming a bigger problem than illegal drugs because… the message ‘legal’ means safe, which it’s not.

He said some of the legal high drugs “are stronger, more potent than the illegal drugs and it’s quite scary. There’s a generation of young people who are being sold a lie that legal means safe.”

“There has been a lot of talk about whether things are appropriately classified and I think the development of these new compounds at the rate they’re being developed probably warrants a second look at how we control all drugs,” he said.

Legal highs are not new but there are more of them and there are concerns they are getting more potent.

Last month the monitoring centre which records drug use across Europe said new highs were appearing at an “unprecedented” pace.

Some 41 new substances emerged in 2010, 16 of which were first reported in the UK.

The most high profile has been mephedrone, which has been linked to a number of young people’s deaths.

The UK government is planning to bring in temporary banning orders, to allow time for legal highs to be tested.

From: http://www.bbc.co.uk/news/uk-wales-13846006

A new 10p a day ‘polypill’ containing aspirin and statins halves the risk of heart disease and stroke, according to the world’s first international trial of the drug.
Researchers found “sizeable reductions” in blood pressure and levels of ‘bad’ cholesterol among those who took the polypill over a 12 week period. Separate pills are already prescribed to millions of people worldwide to lower their chances of heart attack and stroke.

But scientists have been looking at the prospect of a combined pill, which they believe will encourage more people to take the medications more reliably.

Eight years ago Prof Sir Nichlas Wald, who demonstrated that passive smoking causes cancer, proposed the polypill in an article in the British Medical Journal.

He wrote that such an easy-to-take pill could significantly reduce the burden of cardiovascular disease, which is Britain’s biggest killer, accounting for almost 200,000 deaths a year.

Taking such a preventive pill should be as automatic as “brushing your teeth”, he later suggested.

Now the first international polypill study, published and part funded by the Wellcome Trust, has suggested it could be extremely effective.

The researchers examined data from 378 people with a raised risk of cardiovascular disease. Half were given the polypill and half the placebo. About a third of the participants were British, a third Dutch and a third Indian.

Specifically, systolic blood pressure was reduced from a pre-trial average of 134 mmHg to 124; while ‘bad’ LDL cholesterol came down from 3.7 mmol/L to 2.9.

Doctors use mmHg as a standard unit for measuring blood pressure, while mmol/L – millimoles per litre – is used as a measurement unit for very low concentrations of substances in blood.

Cardiologists know that having high blood pressure and cholesterol raises the chances of cardiovascular events, and are able to estimate how much reducing these factors decreases that risk.

The researchers calculated that the polypill would roughly halve the incidence of major cardiovascular events in people with similar risk profiles to the participants.

Writing in the journal Public Library of Science One, they concluded that the benefits to those at a high risk would be even greater: “Overall about one in four high risk people would be predicted to avoid a major event over five years.”

Prof Anthony Rodgers of the George Institute for Global Health in Australia, who led the study, said: “The results show a halving in heart disease and stroke can be expected for people taking this polypill long-term. We are really excited about this – it is a step closer to providing the polypill to patients.”

It has long been known that taking aspirin and statins separately reduces the risk of cardiovascular disease, but this is one of the first studies examining taking them in a combined pill.

It contains 75mg aspirin, 20mg simvastatin, 10mg lisinopril and 12.5mg hydrochlorothiazide. Aspirin prevents blood getting too ‘sticky’, which can lead to clots that cause heart attacks; statins lower cholesterol; while the latter two drugs lower blood pressure.

There were fears that the drugs could react in a pill while being stored, and cancel each other out, but the trial proved these were unfounded.

All four drugs are off patent, meaning any drugs company can manufacture them.

Prof Simon Thom, of Imperial College London, said the Indian pharmaceutical firm Dr Reddys had committed to make the polypill “as dirt cheaply as possible”.

The cost issue is particularly important in poorer and middle income countries, which are facing growing epidemics of ‘lifestyle’ diseases due to changing diets and people getting less exercise.

About 17 million people die of cardiovascular disease every year, 80 per cent of them in developing countries.

Prof Thom said in such countries the cost could be just £1.20 a month, with richer countries which were able to shoulder the economic burden paying more. Even so, the cost in Britain could be as low as £3 a month.

The case for the polypill has been given a powerful boost by British-led research, published in The Lancet last winter, showing that regularly taking low dose aspirin reduces the risk of certain cancers, including bowel cancer, by up to 50 per cent.

Prof Rodgers commented: “These benefits would take several years to ‘kick in’, but of course one of the hopes with a polypill is it helps people take medicines long-term.”

Two years ago Prof Roger Boyle, England’s heart disease ‘czar’, told MPs that he liked the “concept” but there were questions marks over safety. He also said there was a “fine line” between preventive medicine and “medicalising” the population.

Side effects are a big issue. Aspirin is known to aggravate the intestine and can cause internal bleeding, although most cases are minor.

This trial found that about one in 20 people stopped taking the polypill because of side effects, mainly due to such bleeding but also due to light-headedness caused by too low blood pressure.

Prof Rodgers said it was highly unlikely that all middle aged and elderly people would be offered a polypill in the future, but that it could be allocated to those with a higher risk of heart disease, stroke and certain cancers.

That could feasibly be one in five people over 30, perhaps more.

Dr Lorna Layward, from The Stroke Association, said: “Many people with high blood pressure and high cholesterol are required to take multiple pills every day in order to reduce their risk.

“Calculating when each pill needs to be taken can often be confusing and so combining the pills into one could make taking the medication much simpler.

From: http://www.telegraph.co.uk/10p-polypill-halves-heart-disease-and-stroke-risk

Health Direct warns that as the bank holiday weekend approaches that the number of alcohol related hospital admissions in England has topped one million for the first time.
An NHS Information Centre report said admissions had increased by 12% between 2008-09 and 2009-10.

That includes liver disease and mental disorders due to alcohol abuse as well as some cancers, accidents and injuries.

The Department of Health will publish a new alcohol strategy later this year.

The number of admissions reached 1,057,000 in 2009-10 compared with 945,500 in 2008-09 and 510,800 in 2002-03.

Earlier this year the charity Alcohol Concern predicted the number of admissions would reach 1.5m a year by 2015. It estimated that would cost the NHS £3.7bn a year.

Tim Straughan, chief executive of the NHS Information Centre, said: “Today’s report shows the number of people admitted to hospital each year for alcohol related problems has topped 1m for the first time.

“The report also highlights the increasing cost of alcohol dependency to the NHS as the number of prescription items dispensed continues to rise.

“This report provides health professionals and policy makers with a useful picture of the health issues relating to alcohol use and misuse. It also highlights the importance of policy makers and health professionals in recognising and tackling alcohol misuse which in turn could lead to savings for the NHS.”

Professor Sir Ian Gilmore, the chair of the UK Alcohol Health Alliance, said: “This confirms doctors’ impressions that the health harm from alcohol continues to rise.”

“While total alcohol consumption has fallen in recent years it is likely that the number of abstainers in England is increasing, but those who do drink continue to do so in a harmful and destructive way.”

The body which represents drinks manufacturers in the UK, the Portman Group, expressed surprise that admissions had increased at the same time as alcohol consumption had decreased.

David Poley, chief executive of the Portman Group, said: “If the hospital admissions data are robust, they clearly put paid to the argument that measures to reduce overall alcohol consumption are effective in reducing harm.

“The report shows that the proportion of people misusing alcohol is falling. We just need to find a way of persuading and educating this hard core of misusers who account for these admissions to drink responsibly.”

Alcohol Concern said the latest set of figures were alarming but that early detection of alcoholism contributed to the increase.

Its director of policy and communications, Nicolay Sorensen, said: “More people than ever before are drinking in a way that is harming their health and it’s a serious public health problem. It’s one of the biggest public health problems facing the country.

“In addition, the NHS has been doing some great work to identify people that have alcohol problems and so some of the increase is due to better identification and better referral.”

Public Health Minister Anne Milton said: “These statistics show that the old ways of tackling public health problems have not always yielded the necessary improvements.

“We are already taking action to tackle problem drinking, including plans to stop supermarkets selling below cost alcohol and working to introduce a tougher licensing regime.

“We will also be publishing a new alcohol strategy later this year.”

Rates of alcohol-related hospital admissions came down in the past two years in Scotland, after increasing for a decade. In Wales, figures for up to 2006 showed increasing admission rates and in Northern Ireland the total number of admissions increased year on year since 2006/07.

From: http://www.bbc.co.uk/news/health-13559455

New EU red tape has come into force banning hundreds of traditional herbal remedies.
The EU red tape which kicked in on May 1st is claimed to protect consumers from possible damaging side-effects of over-the-counter herbal medicines.

For the first time, new regulations will allow only long-established and quality-controlled medicines to be sold.

But both herbal remedy practitioners and manufacturers fear they could be forced out of business.

To date, the industry has been covered by the 1968 Medicines Act, drawn up when only a handful of herbal remedies were available and the number of herbal practitioners was very small.

But surveys show that about a quarter of all adults in the UK have used a herbal medicine in the past two years, mostly bought over the counter in health food shops and pharmacies.

The regulations will cover widely used products such as echinacea, St John’s Wort and valerian, as well as traditional Chinese and Indian medicines.

But safety concerns have focused on the powerful effects of some herbal remedies, as well as the way they interact with conventional drugs.

For example, St John’s Wort can interfere with the contraceptive pill, while ginkgo and ginseng are known to have a similar effect to the blood-thinning drug warfarin.

From now on only products that have been assessed by the Medicine and Healthcare products Regulatory Agency (MHRA) will be allowed to go on sale.

Manufacturers will have to prove that their products have been made to strict standards and contain a consistent and clearly marked dose.

And to count as a traditional medicine, products must have been in use for the past 30 years, including 15 years within the EU.

They will also only be approved for minor ailments like coughs and colds, muscular aches and pains, or sleep problems.

The manufacturers of herbal remedies have had seven years to prepare for the new rules after the European Directive on Traditional Herbal Medicinal Products was introduced in 2004.

These regulations apply to over-the-counter sales, which form the bulk of herbal remedies sold in the UK.

But some manufacturers and herbal practitioners have expressed concern, arguing the new rules are too onerous for many small producers.

Michael McIntyre, chairman of the European Herbal and Traditional Medicines Practitioners Association, says there will be a significant impact on herbal medicine practitioners and their suppliers, but admits the rules do need bringing up to date.

“Products that go on the market now will definitely do what it says on the bottle, while we didn’t know how good they were in the past.

“But registration is expensive so perhaps there may be fewer products on the market and a smaller range.

“It’s difficult to argue that the market should stay as it is, without any regulation, but how many businesses will pack up and walk away? I can’t say.”

A Department of Health spokesperson said: “We have swiftly introduced a system to register herbal practitioners using unlicensed herbal medicines, so consumers will be able to continue to use unlicensed herbal medicines if they wish.”

A British man has been sentenced to eight years in prison for his role in what law enforcers describe as the “most serious known breach” of the regulated UK medicines supply chain.
Following a four month trial in Croydon Crown Court, 64-year old Peter Gillespie was found guilty for working with an international network of criminals to introduce fake drugs into the UK’s legitimate supply chain during a five month period in 2007.

The case, known as Operation Singapore, centred on the importation of more than two million doses of counterfeit life saving medicines into the country.

More than half of these were captured by the Medicines and Healthcare products Regulatory Agency, but a huge amount – almost 900,000 doses – initially reached pharmacies and patients.

Despite an immediate recall of Eli Lilly’s antipsychotic Zyprexa (olanzapine), Bristol-Myers Squibb’s bloodthinner Plavix (clopidogrel) and AstraZeneca’s prostate cancer drug Casodex (bicalutamide), 700,000 doses were left unaccounted for, putting the health of many Britons in jeopardy.

Mick Deats, the MHRA’s head of enforcement, also revealed that plans to bring in three other counterfeit drugs – Pfizer/Eisai’s Alzheimer’s drug Aricept (donepezil), UCB’s antiepileptic Keppra (levetiracetam) and Johnson & Johnson’s antipsychotic Risperdal (risperidone) – had been foiled.

“They didn’t get to bring them in but they were definitely well on the way to being prepared to receive them,” he told the media, according to Reuters.

“This is serious criminal activity and puts people’s lives at risk,” Deats said, and stressed that the Agency would not hesitate “to take all appropriate action to eliminate the risks posed by counterfeit medicines and take action against those engaged in their supply”.

However, he also noted current evidence suggests that medicines supplied through the UK legitimate supply chain are genuine and safe to take.

Since 2004 there have been just 15 known instances of counterfeit medicines in the UK regulated supply chain, and given that 850 million prescriptions are dispensed every year in the UK, the likelihood of receiving a counterfeit medicine remains extremely rare, the MHRA said.

From: http://www.pharmatimes.com/Man_jailed_for_worst_ever_breach_of_medicines_supply_chain

Researchers at the University of Reading have discovered that three compounds found in cannabis leaves can help to reduce and control seizures in epilepsy.
They are now using extracts from the plants grown in huge industrial-sized greenhouses in the south of England to develop new drugs that could ease the misery of millions of epilepsy sufferers around the world.

In the UK alone there are more than 500,000 people who suffer from epilepsy.

Dr Ben Whalley, who is leading the research at the department of pharmacy at the University of Reading, said tests in animals had shown the compounds effective at preventing seizures and convulsions while also having less side effects than existing epilepsy drugs.

He said: “There was a stigma associated with cannabis that came out from the 60s and 70s associated with recreational use, so people have tended not to look at it medicinally as a result.”

“Cannabis is thought of being a treasure trove of compounds that could be used for pharmacological development. We have a list of around a dozen potential candidates for epilepsy and have tested three that show promise.”

“These compounds are very well tolerated and you are not seeing the same kind of side effects that you get with the existing treatments.”

Epilepsy is caused by sudden bursts of electrical activity in the brain that disrupt the normal way in which messages are transmitted. This can cause debilitating seizures and fits that can lead to sufferers injuring themselves.

Dr Whalley, together with his colleagues Dr Claire Williams and Dr Gary Stephens have been working with drug company GW Pharmaceuticals to develop and test new treatments for the disease from cannabis.

Two of the compounds they have identified, one called cannabidiol and the other called GWP42006, have been highly effective at controlling seizures in animals and the researchers now hope to begin clinical trials in humans within the next three years.

Neither of the compounds produce the characteristic “high” associated with cannabis use.

The scientists, whose latest findings on the compounds are published in the scientific journal Seizure, believe they work by interfering with the signals that cause the brain to become hyper-excitable, which leads to epileptic seizures.

Until now the main medicinal use that has been explored for cannabis has been in treating Multiple Sclerosis and for pain relief in cancer patients.

GW Pharmaceuticals has been given a license to grows around 20 tonnes of cannabis a year at its facilities in a rural part of southern England for medicinal research. In each glasshouse the temperature is carefully maintained at 77 degrees F while the crops are protected by electric fences and 24 hour security.

Mark Rogerson, from GW Pharmaceuticals, said: “Medicinal cannabinoids can treat a wide range of diseases like MS and pain.

“The work by Dr Whalley and his team is taking us into a whole new area where there is a real unmet need. The stigma is counterbalanced by the fact that it is a serious medicine for a serious condition.”

A spokesman for Epilepsy Action said: “Epilepsy is a condition that can be very difficult to treat.

“We are aware of some people with epilepsy who have used cannabis for medicinal purposes. However, it should be noted that although taking cannabis may reduce seizures in some people, it could actually increase seizures in others.

“We therefore welcome research into this treatment area. It could help our understanding of alternative therapies and may prove useful in the long-term for people whose epilepsy does not respond to more traditional methods.”

From: http://www.telegraph.co.uk/Cannabis-could-be-used-to-treat-epilepsy

The emergence of antibiotic resistant infections has reached unprecedented levels and now outstrips our ability to fight it with existing drugs, European health experts are warning.
Each year in the EU over 25,000 people die of bacterial infections that are able to outsmart even the newest antibiotics.

The World Health Organization says the situation has reached a critical point.

A united push to make new drugs is urgently needed, it says.

Without a concerted effort, people could be dealing with the “nightmare scenario” of worldwide spread of untreatable infections, says the WHO.

One example is the New Delhi or NDM-1 superbug recently found in UK patients. They have brought the infection back with them from countries like India and Pakistan, where they had visited for medical treatment and cosmetic surgery.

The Cardiff University researchers, who made the discovery last August, now say bacteria with this new genetic resistance to antibiotics have contaminated New Delhi’s drinking water supply, meaning millions of people there could be carriers.

Dr Timothy Walsh and his team collected 171 swabs of seepage water and 50 public tap water samples from sites within a 12km radius of central New Delhi between September and October 2010.

The NDM-1 gene was found in two of the 50 drinking-water samples and 51 of 171 seepage samples.

Worryingly, the gene had spread to bacteria that cause dysentery and cholera, which can be easily passed from person to person via sewage-contaminated drinking water.

“Oral-faecal transmission of bacteria is a problem worldwide, but its potential risk varies with the standards of sanitation.

“In India, this transmission represents a serious problem… 650 million citizens do not have access to a flush toilet and even more probably do not have access to clean water,” the researchers warn in the journal Lancet Infectious Diseases.

The scientists are calling for urgent action by health authorities worldwide to tackle the new strains and prevent their global spread.

Zsuzsanna Jakab, WHO regional director for Europe, said: “Antibiotics are a precious discovery, but we take them for granted, overuse and misuse them: there are now superbugs that do not respond to any drugs.

“Given the growth of travel and trade in Europe and across the world, people should be aware that until all countries tackle this, no country alone can be safe.”

The UK’s Health Protection Agency said it was monitoring the spread of NDM-1 closely.

“The first case of a bacterial infection with this resistance was identified in January 2008. Monitoring of this resistance began in 2009 as more cases were identified.”

So far, there have been around 70 cases of the infection recorded in the UK.

The HPA insists that the risk of infection to travellers to the Indian subcontinent who are not treated in hospital is minimal.

“If members of the public are travelling for surgery overseas they should satisfy themselves that appropriate infection control measures are in place,” says the HPA.

From: http://www.bbc.co.uk/news/health-12975693

The National Health Service could save around £200 million a year through more efficient prescribing by GPs, a report by the think tank The King’s Fund has found.
While its extensive inquiry into general practice in England praised the majority of care, it found significant variation in prescribing across the country, and that substantial savings could be made if family doctors were more efficient in prescribing certain drugs, particularly statins.

The extensive review also other widespread variations in the quality of care and performance throughout primary care.

For example, one-third of patients with stomach or oesophageal cancer who needed an urgent referral to hospital were actually given a non-urgent referral by GPs.

In fact, overall, an eight-fold variation at which practices urgently refer patients with suspected symptoms of cancer on to specialists in secondary care was found.

Continuity of care continues to be an issue, as only just over a quarter of patients are able to see the doctor of their choice in the lowest performing practices.

Crucially, there were also wide variations in admission rates for patients that could actually be treated outside hospital, which is particularly important as the effective management of patients within the community could also save the NHS hundreds of millions of pounds a year, The King’s Fund said.

On a more general note, the inquiry’s report strongly backs the position of GPs as generalists rather than specialists, but also notes that the profession must embrace the radical changes laid out in the government’s reform of the health system – particularly new commissioning powers -  in order to “maintain its international reputation for excellence”.

In addition, in order to help meet the growing challenges in healthcare, such as the ageing population and increasing demand on service, by building on the changes already taking place within the system.

It calls on GPs to accelerate the trend for multi-professional teams that work closely alongside specialists outside the practice, move away from being ‘gatekeepers’ to ‘navigators’ who essentially co-ordinate care for people with complex needs, and place a greater emphasis on prevention of ill health.

There must also be a much stronger focus on improving the quality of care, the report notes, and also calls on GPs to take responsibility for driving forward progress through a stronger commitment to transparency, particularly on performance data, peer review and benchmarking, and better data capture and use of information.

“Although general practice in this country remains the envy of the world, there is no room for complacency,” warned The King’s Fund’s chief executive Chris Ham.

“While many practices have been at the vanguard of innovation and quality improvement, too many GPs remain unaware of significant variations in performance and do not give priority to improving quality,” he noted.

NHS Confederation acting chief executive Nigel Edwards said improving primary care and GP services is one of the biggest challenges facing the NHS, and that the report “highlights the need to address the major variations in the standards of care patients are receiving”.

He calls for the introduction of a national process to compare general practice standards which, he claims, would not only empower patients to compare the standard of care, but would also help “drive down variation in diagnosis, referrals and prescriptions, all of which are central to saving lives”.

According to the British Medical Association a “culture of self-scrutiny has existed for many years but now more than ever, given the increased intensity and complexity of general practice work nowadays, GPs need time off the treadmill so they can look critically at what they do and make improvements”.

“A reduction in bureaucracy would help them to do this, as would stopping the constant reorganisations within the NHS”, it stressed.

From: http://www.pharmatimes.com/NHS_could_save_millions_of_pounds_with_better_prescribing

The “war on drugs” has failed and should be abandoned in favour of evidence based policies that treat addiction as a health problem, according to prominent public figures including former heads of MI5 and the Crown Prosecution Service.
Leading peers – including prominent Tories – say that despite governments worldwide drawing up tough laws against dealers and users over the past 50 years, illegal drugs have become more accessible.

Vast amounts of money have been wasted on unsuccessful crackdowns, while criminals have made fortunes importing drugs into this country.

The increasing use of the most harmful drugs such as heroin has also led to “enormous health problems”, according to the group.

The MPs and members of the House of Lords, who have formed a new All-Party Parliamentary Group on Drug Policy Reform, are calling for new policies to be drawn up on the basis of scientific evidence.

It could lead to calls for the British government to decriminalise drugs, or at least for the police and Crown Prosecution Service not to jail people for possession of small amounts of banned substances.

Their intervention could receive a sympathetic audience in Whitehall, where ministers and civil servants are trying to cut the numbers and cost of the prison population. The Justice Secretary, Ken Clarke, has already announced plans to help offenders kick drug habits rather than keeping them behind bars.

The former Labour government changed its mind repeatedly on the risks posed by cannabis use and was criticised for sacking its chief drug adviser, Prof David Nutt, when he claimed that ecstasy and LSD were less dangerous than alcohol.

The chairman of the new group, Baroness Meacher – who is also chairman of an NHS trust – told The Daily Telegraph: “Criminalising drug users has been an expensive catastrophe for individuals and communities.

“In the UK the time has come for a review of our 1971 Misuse of Drugs Act. I call on our Government to heed the advice of the UN Office on Drugs and Crime that drug addiction should be recognised as a health problem and not punished.

“We have the example of other countries to follow. The best is Portugal which has decriminalised drug use for 10 years. Portugal still has one of the lowest drug addiction rates in Europe, the trend of Young people’s drug addiction is falling in Portugal against an upward trend in the surrounding countries, and the Portuguese prison population has fallen over time.”

Lord Lawson, who was Chancellor of the Exchequer between 1983 and 1989, said: “I have no doubt that the present policy is a disaster.

“This is an important issue, which I have thought about for many years. But I still don’t know what the right answer is – I have joined the APPG in the hope that it may help us to find the right answer.”

Other high-profile figures in the group include Baroness Manningham-Buller, who served as Director General of MI5, the security service, between 2002 and 2007; Lord Birt, the former Director-General of the BBC who went on to become a “blue-sky thinker” for Tony Blair; Lord Macdonald of River Glaven, until recently the Director of Public Prosecutions; and Lord Walton of Detchant, a former president of the British Medical Association and the General Medical Council.

Current MPs on the group include Peter Bottomley, who served as a junior minister under Margaret Thatcher; Mike Weatherley, the newly elected Tory MP for Hove and Portslade; and Julian Huppert, the Liberal Democrat MP for Cambridge.

The group’s formation coincides with the 50th anniversary of the United Nations Single Convention on Narcotic Drugs, which paved the way for a war on drugs by describing addiction as a “serious evil”, attempting to limit production for medicinal and scientific uses only, and coordinating international action against traffickers.

The peers and MPs say that despite governments “pouring vast resources” into the attempt to control drug markets, availability and use has increased, with up to 250 million people worldwide using narcotics such as cannabis, cocaine and heroin in 2008.

They believe the trade in illegal drugs makes more than £200 billion a year for criminals and terrorists, as well as destabilising entire nations such as Afghanistan and Mexico.

As a result, the all-party group is working with the Beckley Foundation, a charitable trust, to review current policies and scientific evidence in order to draw up proposed new ways to deal with the problem.

From: http://www.telegraph.co.uk/War-on-drugs-has-failed-say-former-heads-of-MI5-CPS-and-BBC